Lenalidomide: a review of its continuous use in patients with newly diagnosed multiple myeloma not eligible for stem-cell transplantation
Abstract
Lenalidomide (Revlimid(®)) is a second-generation immunomodulatory drug structurally related to thalidomide, with improved efficacy and tolerability, for which the label in the EU was recently expanded to include continuous therapy in patients with previously untreated multiple myeloma not eligible …
Keywords
National Center for Biotechnology Information
NCBI
NLM
MEDLINE
review
animals
clinical trials as topic
humans
pubmed abstract
nih
national institutes of health
national library of medicine
treatment outcome
Angiogenesis Inhibitors / therapeutic use*
prednisone / therapeutic use
antineoplastic combined chemotherapy protocols / therapeutic use
Melphalan / therapeutic use
lenalidomide
multiple myeloma / drug therapy*
thalidomide / adverse effects
thalidomide / analogs & derivatives*
pmid:25925941
doi:10.1007/s40266-015-0269-6
paul l mccormack
angiogenesis inhibitors / adverse effects
angiogenesis inhibitors / pharmacology
stem cell transplantation
thalidomide / pharmacology
thalidomide / therapeutic use
Access
Citation
ID:
270181
References
Blockchain Verification
Account:
NFT Contract Address:
0x95644003c57E6F55A65596E3D9Eac6813e3566dA
Article ID:
270181
Unique Identifier:
Network:
Scimatic Chain (ID: 481)
Loading...
Blockchain Readiness Checklist
Authors
Abstract
Journal Name
Year
Title
Creates 1,000,000 NFT tokens for this article
Token Features:
- ERC-1155 Standard NFT
- 1 Million Supply per Article
- Transferable via MetaMask
- Permanent Blockchain Record
Scan with Saymatik Web3.0 Wallet
